Claims for Patent: 9,943,649

Summary for Patent: 9,943,649

Title:	Automatic injection device
Abstract:	Automatic injection device includes a housing, a syringe, a plunger, and a syringe carrier. The housing includes a barrel between a first end and a second end. The barrel includes an elongated window to allow viewing of contents inside the housing. The syringe is disposed within the housing and has a reservoir. The plunger is at least partially disposed within the syringe and includes a visual indicator. The syringe carrier is disposed within the housing and configured to contain the syringe and displace the syringe within the housing between a first position and a second position. The syringe carrier can be substantially transparent. The syringe carrier can have first and second legs and an extension disposed therebetween, and at least a portion of the extension can be configured to align with the window and the reservoir when the syringe carrier is in the first position.
Inventor(s):	Shang; Sherwin (Vernon Hills, IL), Tsvirko; Eduard (Arlington Heights, IL), Chim; Edwin (Vernon Hills, IL), Somashekar; Shubha Chethan (Waukegan, IL), Ozdaryal; Esra (Deerfield, IL), Julian; Joseph F. (Libertyville, IL), Li; Chuan (Deerfield, IL)
Assignee:	AbbVie Inc. (North Chicago, IL)
Application Number:	14/220,782
Patent Claims:	1. An automatic injection device comprising: a housing having a first end, a second end, and a barrel between the first end and the second end, the barrel comprising an elongated window to allow viewing of contents inside the housing; a syringe disposed within the housing and having a first end, a second end, and a reservoir between the first end and the second end; a plunger at least partially disposed within the syringe and comprising a visual indicator on a portion of the plunger; and a syringe carrier disposed within the housing and configured to contain the syringe and displace the syringe within the housing between a first position and a second position, the syringe carrier being substantially transparent and having first and second legs defining at least a portion of at least one opening configured to align with the window and the reservoir when the syringe carrier is in the first position. 2. The automatic injection device of claim 1, the housing further comprising a beveled edge surrounding the elongated window to receive a shield. 3. The automatic injection device of claim 2, wherein the shield is configured to prevent UV radiation from entering the housing through the elongated window. 4. The automatic injection device of claim 1, wherein the elongated window has a substantially symmetrical oval shape. 5. The automatic injection device of claim 1, wherein the elongated window has at least one tapered portion extending along a length thereof. 6. The automatic injection device of claim 1, the at least one opening comprising a first opening configured to align with the window and the reservoir when the syringe carrier is in the first position. 7. The automatic injection device of claim 6, wherein the syringe carrier is configured to allow viewing of substantially all of a liquid therapeutic agent in the reservoir when the syringe carrier is in the first position. 8. The automatic injection device of claim 6, the at least one opening further comprising a second opening configured to align with the window and the visual indicator when the syringe carrier is in the second position. 9. The automatic injection device of claim 8, the syringe carrier further comprising a middle portion between the first and second openings, the middle portion sized to resist deformation of the syringe carrier. 10. The automatic injection device of claim 8, wherein the first opening is positioned nearer to the first end of the housing than the second opening. 11. The automatic injection device of claim 1, the syringe carrier further comprising first and second pairs of legs, and the at least one opening comprising a front opening portion and a diametrically opposed rear opening portion, the first pair of legs defining at least a portion of the front opening portion and the second pair of legs defining at least a portion of the rear opening portion. 12. The automatic injection device of claim 1, wherein the first position is a pre-injection position. 13. The automatic injection device of claim 1, wherein the second position is a post-injection position. 14. The automatic injection device of claim 1 further comprising a cap having an outer portion, the first end of the housing configured to receive the outer portion of the cap, the outer portion of the cap comprising a cap notch, a portion of the elongated window being aligned with the cap notch when the cap receives the housing to prevent obstruction of the window. 15. The automatic injection device of claim 1, further comprising a shroud at least partially disposed within the housing, a portion of the shroud disposed within the housing having a shroud notch, the shroud notch being aligned with at least a portion of the elongated window to prevent obstruction of the window. 16. The automatic injection device of claim 1, further comprising a liquid therapeutic agent in the reservoir, the liquid therapeutic agent having a volume of 0.4 mL. 17. The automatic injection device of claim 1, further comprising a liquid therapeutic agent in the reservoir, the liquid therapeutic agent having a volume of 0.8 mL. 18. The automatic injection device of claim 1, further comprising a liquid therapeutic agent in the reservoir, the liquid therapeutic agent comprising a protein. 19. The automatic injection device of claim 1, further comprising a liquid therapeutic agent in the reservoir, the liquid therapeutic agent comprising adalimumab.

Details for Patent 9,943,649

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2031-09-22
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2031-09-22
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2031-09-22
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014		2031-09-22
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11/23/2015		2031-09-22
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	03/09/2016		2031-09-22